In spite of the lack of clinical evidence for PARPi treatment efficacy in PALB2-deficient breast cancer patients, the response of some other PALB2-deficient solid tumors to PARPi in clinical/preclinical studies have been remarkable. This evidence concerns the gene PALB2 and breast cancer.